Other Events ·
On September 14, 2026, Agomab Therapeutics NV announced positive Phase 1 results for AGMB-447 in patients with…
AGMBAgomAb Therapeutics NV
On September 14, 2026, Agomab Therapeutics NV announced positive Phase 1 results for AGMB-447 in patients with Idiopathic Pulmonary Fibrosis (IPF). The study demonstrated a favorable safety profile at the 4.5 mg twice-daily dose and confirmed robust target engagement of ALK5 via pSMAD3 reduction exceeding 50%. Pharmacokinetic data showed efficient lung restriction with low systemic exposure. The company submitted a Clinical Trial Application for the Phase 2 INSPIRIA study, which will enroll approximately 120 IPF patients in a randomized, double-blind trial evaluating forced vital capacity changes over 24 weeks. Agomab intends to initiate this study before year-end across European sites. Agomab Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibro-inflammatory diseases.